sunil acharya
@sunilacharya13
Cancer Research, CAR-NK, Biotech, Premier League, Premier League Fantasy, Nepal, MD Anderson Cancer Center
ID: 823800032
14-09-2012 18:58:24
560 Tweet
365 Followers
565 Following
It was a true pleasure to present! Thank you so much BMDACC Stem Cell Program for the opportunity to share our work on NK cell therapy! Really enjoyed the meeting and the outstanding talks! MD Anderson Cancer Center Katy Rezvani, M.D., Ph.D
We are so excited to share receipt of award notice for our multi-PI R01 with Rafet and Katy Rezvani, M.D., Ph.D to explore novel CAR NK cellular therapies for #pancreaticcancer! We are grateful to the NCI Center for Cancer Research and our collaborators Anirban Maitra MD Anderson Cancer Center #endpdac #endcancer #nk
The future is bright for NK cell therapy with so many innovative products and scientific discoveries in the pipeline 🤩! Katy Rezvani, M.D., Ph.D MD Anderson Cancer Center #NK #Engineering #CAR
Deeply grateful to the SU2C MEG VOSBURG T-CELL LYMPHOMA DREAM TEAM for supporting our CAR NK program to target CD5. And thrilled to share FDA clearance for a clinical trial targeting CD5 CAR NK cells in patients with T cell lymphoma. Stand Up To Cancer MD Anderson Cancer Center
Tour de force presentation today by Dr. Katy Rezvani Katy Rezvani, M.D., Ph.D at the Allison Institute MD Anderson Cancer Center encompassing great science and a proliferative pipeline of cell therapies for our patients with heme and solid cancers! #NK #celltherapy
it was an honor to present some of our data supporting the role of allogeneic #CARNK cells in #myeloma & #lymphoma at the Experts of Transplantation Thank you for invitation Meral Beksac Tolga Sutlu Katy Rezvani, M.D., Ph.D
It was an honor to present some of our research and clinical findings at the #CIMT20224 about the role of allogeneic #CARNK cells in various diseases. Katy Rezvani, M.D., Ph.D MD Anderson Cancer Center Cancer Immunotherapy
It was a pleasure to present at the 9th Kaunas/Lithuania International Hematology/Oncology Colloquium on our work in NK cells and our preclinical efforts to tackle the solid TME. Big thanks to Prof Niederwieser and the organizers for the invite. MD Anderson Cancer Center Katy Rezvani, M.D., Ph.D
Hind Rafei is an assistant professor in the Department of Stem Cell Transplantation and Cellular Therapy MD Anderson Cancer Center. She is a remarkable physician-scientist who is especially focused on using Natural Killer (NK) cells as a #celltherapy against cancer. Follow her Hind Rafei!
Research led by Dr. Katy Rezvani found that the addition of CD28, a molecule that is normally absent in mature NK cells, can enhance CAR NK function in blood and solid tumors. Read how this could enhance NK cell therapies: bit.ly/4c8Zgl8 Katy Rezvani, M.D., Ph.D #EndCancer
#OnlineFirst: CD28 costimulation augments CAR signaling in NK cells via the LCK/CD3Z/ZAP70 signaling axis, by sunil acharya, Katy Rezvani, M.D., Ph.D et al. bit.ly/3REXzU6 MD Anderson Cancer Center
Exciting research on CD70-targeting CAR NK cells - Katy Rezvani, M.D., Ph.D Elizabeth McKenna sunil acharya MD Anderson Cancer Center Cancer Discovery Ken Chen NV Lab oncodaily.com/insight/89083.… #Cancer #CancerResearch #Immunotherapy #OncoDaily #Oncology
Happy to share our new NK cell resource in Nature Immunology: "Pan-cancer profiling of tumor-infiltrating natural killer cells through transcriptional reference mapping." nature.com/articles/s4159…. Herman K. Netskar, Aline Pfefferle, Horowitz Lab @Icahn School of Medicine Mount Sinai Human Cell Atlas, Precision Immunotherapy Alliance, UiO - Det medisinske fakultet
CAR NK cells with CD28 costimulation improved cell persistence and antitumor activity Cancer Discovery MD Anderson Cancer Center sunil acharya May Daher Hind Rafei Mayra Shanley Bijender Kumar Katy Rezvani, M.D., Ph.D Dr. Elizabeth Shpall oncodaily.com/98405.html #Cancer #CancerResearch #OncoDaily #Oncology
Honored to join this distinguished panel at #SITC24! Looking forward to discussing the latest advancements in NK cell and innate immunity research with esteemed colleagues Eric Vivier, Marco Colonna, and Nicholas Huntington. Don’t miss this session! See you in Houston in November!
Delighted to share our latest research published in Cancer Cell Cell. Our study shows that intratumoral administration of IL-21 engineered NK cells resulted in strong and sustained antitumor activity against glioblastoma compared to IL-15 NK cells, which carried significant
Congrats! to my very dear friend Mayra Shanley and Katy Rezvani, M.D., Ph.D for this remarkable work. It has been fun sharing the office with you and witness this inspiring journey. Cheers to many more accomplishments.